According to Reuters at 02/15/2018 U.S. officials warn 'intense' flu season to continue, urge shots.
A total of 63 children in the United States have died of influenza this season, and three-quarters of them did not get a vaccine. This flu season continues to be extremely challenging and intense, with very high levels of office visits for flu and hospitalization rates, all indications that flu activity is high and likely to continue for several more weeks, Flu symptom rates are close to those seen in the 2009 H1N1 flu pandemic and for the past few weeks the whole country has been experiencing the flu . As many as 646,000 people are dying globally from seasonal influenza each year, U.S. health officials said in December, a rise from earlier assessments of the disease’s death toll. With all of this, I can find so many reasons to say the demand for flu vaccine is surging high more for this year and even more for the coming years. Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company's lead adjuvant for human applications, Matrix-M, is in Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. So many investors and traders wait for the next news about their Nanoflu vaccine which it could be the key to any next possible movement.My rate for this stock is Strong hold /Buy with 5 $ Price target for the next 25 days.
Important note : I am uncertified technical chart analysis and I do not have any insider trading or position at this stock, you own your decision to buy, hold or sell this stock.
How I became a successful trader this is the simple answer visit this if you interested to be too https://tinyurl.com/y8pq9496 .
Share on Facebook
Share on Twitter
I'm busy working on my blog posts. Watch this space!